Orteq
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
£8.0m | Series B | ||
N/A | Seed | ||
Total Funding | $10.6m |
Related Content
Recent News about Orteq
EditOrteq Sports Medicine specializes in developing innovative joint preservation solutions aimed at orthopedic sports medicine surgeons. The company focuses on creating products that encourage the body's natural healing process, particularly for younger patients who lack satisfactory treatment options. Orteq's flagship product, ACTIfit, is designed to support the regeneration of meniscus defects through minimally invasive keyhole arthroscopic surgery. The company operates in the healthcare market, serving orthopedic surgeons and their patients. Orteq's business model revolves around the development, clinical validation, and commercialization of its medical devices. Revenue is generated through the sale of these specialized products to healthcare providers globally. The company has a significant presence, with 25 clinical studies, operations in 30 countries, and over 4,000 patients treated. Orteq has also received an FDA Breakthrough Designation for its ACTIfit technology, highlighting its innovative approach to joint preservation.
Keywords: joint preservation, orthopedic, sports medicine, natural healing, ACTIfit, meniscus regeneration, keyhole surgery, healthcare innovation, FDA Breakthrough, global reach.